Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients.

Lin TT, Chen YH, Wu YP, Chen SZ, Li XD, Lin YZ, Chen SH, Zheng QS, Wei Y, Xu N, Xue XY.

J Cancer. 2019 Sep 7;10(22):5608-5613. doi: 10.7150/jca.30731. eCollection 2019.

2.

[Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].

Ji GJ, Huang C, Song G, Li XS, Song Y, Zhou LQ.

Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Aug 18;49(4):657-662. Chinese.

3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.

Hamano I, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C.

World J Urol. 2019 Nov;37(11):2365-2373. doi: 10.1007/s00345-019-02664-3. Epub 2019 Feb 7.

PMID:
30729312
6.
7.

A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.

Jo JK, Oh JJ, Kim YT, Moon HS, Choi HY, Park S, Ho JN, Yoon S, Park HY, Byun SS.

Oncotarget. 2017 May 30;8(57):96893-96902. doi: 10.18632/oncotarget.18298. eCollection 2017 Nov 14. Erratum in: Oncotarget. 2018 Aug 7;9(61):31938. Jo, Jung Ku [corrected to Jo, Jung Ki].

8.

Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.

Qu M, Zhu F, Chen H, Lian B, Jia Z, Shi Z, Li J, Wang Y, Sun Y, Gao X.

J Endourol. 2019 Jul;33(7):570-575. doi: 10.1089/end.2019.0108. Epub 2019 May 31.

PMID:
31025578
9.

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.

Pei X, Wu K, Sun Y, Gao X, Gou X, Xu J, Gao F, He D, Li L; Chinese Prostate Cancer Consortium.

Urol Oncol. 2020 Jan;38(1):2.e11-2.e17. doi: 10.1016/j.urolonc.2019.07.014. Epub 2019 Oct 28.

PMID:
31672485
10.

Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

Kim M, Lee J, Jeong CW, Ku JH, Kim HH, Kwak C.

Urol Oncol. 2015 May;33(5):203.e1-9. doi: 10.1016/j.urolonc.2015.01.017. Epub 2015 Feb 26.

PMID:
25726498
11.

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy.

Min K, Chung JW, Ha YS, Lee JN, Kim BS, Kim HT, Kim TH, Yoo ES, Kwon TG, Chung SK, Tanaka M, Egawa S, Kimura T, Choi SH.

World J Mens Health. 2019 Jun 4. doi: 10.5534/wjmh.190029. [Epub ahead of print]

12.

Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.

Sasaki T, Onishi T, Hoshina A.

Endocr Relat Cancer. 2012 Sep 21;19(5):725-30. doi: 10.1530/ERC-12-0133. Print 2012 Oct.

PMID:
22807499
13.

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.

Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK.

Cancer. 2009 Mar 1;115(5):981-7. doi: 10.1002/cncr.24064.

14.

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.

Afriansyah A, Hamid ARAH, Mochtar CA, Umbas R.

F1000Res. 2018 Feb 28;7:246. doi: 10.12688/f1000research.14026.1. eCollection 2018.

15.

Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.

Huang H, Chen S, Li W, Bai P, Wu X, Xing J.

Clin Genitourin Cancer. 2019 Oct;17(5):e1036-e1047. doi: 10.1016/j.clgc.2019.06.001. Epub 2019 Jun 13.

PMID:
31281063
16.

Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.

Hammerich KH, Donahue TF, Rosner IL, Cullen J, Kuo HC, Hurwitz L, Chen Y, Bernstein M, Coleman J, Danila DC, Metwalli AR.

Urol Oncol. 2017 Jul;35(7):460.e21-460.e28. doi: 10.1016/j.urolonc.2017.02.001. Epub 2017 Apr 11.

PMID:
28410987
17.

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.

Kim KB, Jo JK, Ahn S, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE.

Korean J Urol. 2015 Aug;56(8):580-6. doi: 10.4111/kju.2015.56.8.580. Epub 2015 Aug 6.

18.

[Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].

Kuromoto A, Tanaka T, Koyama J, Goto T, Kimura S, Katsumata Y, Myoen S, Ozawa M, Morozumi K, Sato M, Hoshi S, Numahata K, Arai Y.

Hinyokika Kiyo. 2017 Dec;63(12):515-520. doi: 10.14989/ActaUrolJap_63_12_515. Japanese.

19.

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.

Wu G, Huang S, Nastiuk KL, Li J, Gu J, Wu M, Zhang Q, Lin H, Wu D.

Prostate. 2015 May;75(7):777-782. doi: 10.1002/pros.22967. Epub 2015 Mar 1.

20.

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.

Shigeta K, Kosaka T, Hongo H, Yanai Y, Matsumoto K, Morita S, Mizuno R, Shinojima T, Kikuchi E, Oya M.

Int J Clin Oncol. 2019 May;24(5):546-553. doi: 10.1007/s10147-018-01388-5. Epub 2019 Jan 2. Erratum in: Int J Clin Oncol. 2019 Mar 2;:.

PMID:
30604159

Supplemental Content

Support Center